Fast Screening of Billions of Small Molecule Compounds

DNA-Encoded Library (DEL) technology involves a novel affinity selection process that integrates chemistry, biology, bioinformatics and computational chemistry to facilitate a rapid drug discovery process, allowing access to more chemical space with lower cost.

In contrast to high throughput screening, DEL requires a very small amount of target protein and minimum assay development. More importantly, it disrupts the concept of “cost-per-well” and allows testing billions of compounds in one tube.

Target confidentiality for academics users | Open source

Target confidentiality for all drug developers | Easy access with reduced risk

Target exclusivity for all drug developers | Access to unique scaffolds

• 80+ billion synthetic compounds for diversity
• 100+ selective hot cores for latent druggability of compounds
• 35,000+ commercially source building blocks in stock

• Unique multiple on-DNA reactions to build various chemical bonds
• Flexible library construction to accommodate clients’ needs
• Robust and strict quality to control procedures

Irreversible Covalent Modification

• Specially designed covalent DEL collection featuring diverse warheads targeting Cys, Lys, Tyr, or Ser
• Curated warhead set balancing reactivity and selectivity
• Optimized selection method enhancing the signal-to-noise ratio
• View our publication: Discovery of SARS-CoV-2 Main Protease Covalent Inhibitors from a DNA-Encoded Library Selection

Peptide Discovery

• Direct screening of peptide hits with enhanced affinity, specificity and improved degradation stability by incorporating 1000+ unnatural amino acids
• Various cyclization strategies established for peptide DEL customization
• Serving as an ideal tool for optimizing initial peptide hits from phage and mRNA display*
• View our publication: DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2–p53 Inhibitor

RNA as a Target

• Specialized DEL screening workflows optimized for charge compatibility and diverse RNA structures, while mitigating off-target RNA/DNA interactions to ensure high-confidence hits and accelerate drug discovery
• RNA-targeting focused DEL collection with specific scaffolds based on the structural motifs of known RNA binders
• View our publication: Development of a DNA-encoded library screening method “DEL Zipper” to empower the study of RNA-targeted chemical matter